Pharmacovigilance World 2023
Online event

Pharmacovigilance World 2023

01.11.2023 - 02.11.2023 London, United Kingdom, London
Visit the official Organizer website to ensure the accuracy of the event
Category: Medical & Pharma, Pharmaceuticals
Organizer: Corvus Global Events
Exhibition center: London

Overview interest facts - Pharmacovigilance World 2023

The Pharmacovigilance World 2023 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and how it contributes to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field. Our Pharmacovigilance conferences are known for bringing the world-class leaders together to connect, learn and network. The conference will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.

With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment methods and drugs. However, evidence suggests though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading causes of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance briefs the potential implications of such trends on the evolution of science.

However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc.

Key Highlights:

Pharmacovigilance and globalization
Pharmacovigilance in a pandemic world
Women and child health care medicines and pharmacovigilance
Patient-centric approaches in PV
Pharmacovigilance legislation and regulations
Harmonization and pharmacovigilance
Advanced therapeutic techniques and pharmacovigilance
Pharmacovigilance and data management and eudravigilance
Post-marketing surveillance in pharmacovigilance
PV regulations and challenges
Benefit-risk management strategies
Risk management and minimization
Risk Evaluation and Mitigation
Adverse drug reactions reporting
Signal detection and post authorization safety
Good Pharmacovigilance Practices
Innovative approaches to drug safety
Strategies to improve PV
Real World Evidence in PV
Big data and AI in pharmacovigilance
Pharmacovigilance Workflows with AI & Automation
Other emerging technologies in PV

Who should attend the conference?

Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of
Pharmacovigilance
Safety & Risk management
Drug safety
PV Compliance
Safety Surveillance
Medical Affairs
Regulatory Affairs
Inspection and Audit
Pharmacoepidemiology
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing


News

​AstraZeneca adds to rare blood disease portfolio with world-first Voydeya approval in Japan

A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence...

22 January 2024
​New material improves treatment of complex bone infections

Researchers in Ireland have combined antimicrobial implants and gene therapies to develop a new surgical solution with the potential to improve the treatment of comple...

29 November 2023
Sepsis - as common as cancer, as deadly as a heart attack

In 2016, the research team conducted an initial study in southern Sweden (Skåne) where they revealed that sepsis is much more common than previously believed.

04 September 2023
​FDA approves first oral treatment for postpartum depression

Following the approval, Biogen plans for the commercial launch Zurzuvae (zuranolone) in Q4 2023.

10 August 2023
​New blood test finds two thirds of cancers

A new multi-cancer early detection blood test could speed up diagnosis.

16 June 2023
​EU Proposes Drug Manufacturing Overhaul, Faces Pushback

The European Union on April 26 has released a draft of the probable and proposed revamp of its drug manufacturing laws

04 May 2023
All news